TD Cowen Reiterates Buy on Revolution Medicines, Announces $250 Price Target
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsReiterationPrice Target
TD Cowen analyst Tyler Van Buren reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $250 price target.
TD Cowen analyst Tyler Van Buren reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $250 price target.